India's pharmaceutical industry, known for being a major player in global healthcare, is projected to reach an impressive value of USD 450 billion by 2047. India continues to be a major player in the international pharmaceutical market, with...
The increasing preference for biologics and biosimilars is fueling the demand for the sterile injectable contract manufacturing sector. The market size for sterile injectable contract manufacturing was worth USD 15.96 billion in 2024 and is...
The growth of the global manufacturing execution system in life sciences market is due to the rising need for real-time data and analytics and increasing regulatory compliance. The pharmaceutical sector is quickly embracing digital technology...
Many pharmaceutical companies prioritize digital transformation to enhance their ability to collect, analyze, and store data for future use, driving the increasing demand for the pharma 4.0 market. Utilizing industry 4.0 technology in the...
India exports a large amount of Pharmaceuticals to more than 200 countries around the world. The current worth of the pharmaceutical sector in India is $50 billion. India meets more than half of Africa's generic drug needs, 40% of generic drug...
The pharmaceutical analytical testing market is experiencing substantial expansion due to increased complexity in drug development and growing need for biologics and biosimilars, as per the report by Straits Research Pvt. Ltd...
India is often referred to as the "pharmacy of the world," and its pharmaceutical industry is renowned for producing high-quality generic drugs. These generics not only meet the demand in the Indian domestic market but are also widely exported across
Lupin has one of the quickest increases in the S&P Global ESG scores among pharmaceutical companies in India. Lupin Limited, a leading pharmaceutical company, reported an increase in its S&P Global ESG scores from 69 to 76, surpassing the industry...
India's healthcare system favors curative care, with 38% of spending going towards in-patient services and treatments, compared to just 14% for preventative care. Healthcare costs are also rising, with claim sizes up 11.4% and medical inflation at...
The country's top pharmaceutical companies experienced a 10 per cent year-on-year (YoY) growth in the second quarter of FY25, mainly due to their strong performance in North America and the domestic market, as per Axis Securities report...
, CDSCO.jpg)
